Vol. 43 | No. 1 | January-June 2015Back

Open Access

A Retrospective Cohort Study to Evaluate the Use of Paracetamol Compared to Ibuprofen in the Medical Closure of Patent Ductus Arteriosus Among Preterm Infants in a Private Tertiary Hospital

Maria Ronella T. Francisco
Jun 2015 DOI 10.69944/pjc.7e6801fb26

More Info

Maria Ronella T. Francisco, MD 

References
  1. Sinha R, Negi V, Dalai S, An Interesting Observation of PDA Closure  with Oral Paracetamol in Preterm Neonates. J ClinNeonatol. 2013  Jan-Mar;2(1):30. 
  2. Hamrick S, Hansmann G. Patent Ductus Arteriosus of the Preterm  Infant. Pediatrics. 2010;125;1020. 
  3. Hammerman C, Bin-Nun A, Markovitch E, Schimmel M, Kaplan  M, Fink D, Ductal closure with paracetamol: a surprising new  approach to patent ductus arteriosus treatment. Pediatrics. 2011  Dec;128(6):e1618-21. 
  4. Hofman, JI, Kaplan S. The incidence of congenital heart disease. J  Am CollCardiol. 2002;39(12):1890-1900. 
  5. The Vermont-Oxford Trials Network: Very low birthweight  outcomes for 1990. Pediatrics. 1993;91(3):540-5. 
  6. Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent Ductus  Arteriosus in Preterm Infants: Do We Have the Right Answers?  Biomed Res Int. 2013;2013:676192.  
  7. Zecca E. Romagnoli C. De Carolis MP. Costa S. Marra R. De  Luca D. Does Ibuprofen increase neonatal hyperbilirubinemia?  Pediatrics. 2009 Aug;124(2):480-4.  
  8. Rheinlaender C. Helfenstein D. Walch E. Berns M. Obladen M.  Koehne P. Total serum bilirubin levels during cyclooxygenase  inhibitor treatment for patent ductus arteriosus in preterm infants.  ActaPaediatr. 2009 Jan;98(1):36-42. 
  9. Yurttutan S. Oncel MY. Arayıcı S. Uras N. Altug N. Erdeve O.  Dilmen U. A different first-choice drug in the medical management  of patent ductus arteriosus: oral paracetamol. J Matern Fetal  Neonatal Med. 2013May;26(8):825-7. 
  10. Oncel MY, Yurttutan S, Erdeve O, UrasN,Altug N, Orguz S,  Canpolat FE, Dilmen U. Oral Paracetamol versus Oral Ibuprofen  in the Management of patent Ductus Arteriosus in Preterm Infants:  A Randomized Controlled Trial.J Pediatr. 2014 Mar;164(3):510-4.e1. 
  11. Green K, Drvota V, Vesterqvist O. Pronounced reduction of on vivo  prostacyclin synthesis in humans by paracetamol. Prostaglandins  1989;37:311-5. 
  12. Clyman RI: Mechanisms regulating the ductus arteriosus. Biol  Neonate. 2006;89(4):330-5. 
  13. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF.  The modern pharmacology of paracetamol: therapeutic actions,  mechanism of action, metabolism, toxicity and recent pharmacologic  findings. 
  14. Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action.  PaediatrAnaesth. 2008;18:915-21. 
  15. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus  arteriosus in premature infants by inhibition of prostaglandin  synthesis. N Engl J Med. 1976;295(10):530-3. 
  16. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick  SE. Pharmacologic closure of patent ductus arteriosus in the  premature infant. N Engl J Med. 1976;295(10):526-9. 
  17. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus  arteriosus in preterm and/or low birth weight infants. Cochrane  Database Syst Rev. 2006;1:CD004213.  
  18. Jones LJ, Craven PD, Attia J, Thakkinstian A, Wright I. Network  meta-analysis of indomethacin versus ibuprofen versus placebo  for PDA in preterm infants. Arch Dis Child Fetal Neonat Ed.  2011;96:F45-52. 
  19. Allegaert K, Anderson B, Simons S. Paracetamol to induce ductus  arteriosus closure: is it valid? Arch Dis Child.2013; 98:462-6.
  20. Nadir E, Kassem S, Foldi, Hochberg A, Feldman M. Paracetamol  treatment of patent ductus arteriosus in preterm infants. Journal of  Perinatology. 2014:34,748–9  
  21. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison  of oral paracetamol versus ibuprofen in premature infants with  patent ductus arteriosus: a randomized controlled trial. PLoS One  2013 Nov 4;8(11):e77888 
  22. Yokoyama U, Minamisawa S, Quan H, et al. Chronic activation  of the prostaglandin receptor EP4 promotes hyaluronan mediated  neointimal formation in the ductal arteriosus. J Clin Invest  2006;116(11):3026-34
  23. Mason CA, Chang P, Fallery C, Rabinovitch M. Nitric oxide  mediates LC-3-dependent regulation of fibronectin –dependent  neointimal cushion formation. FASEB J. 1999;13 (11):1423-34. 
  24. Agrawaln S, Fitzsimons JJ, Horn V, Petros A. Intravenous  paracetamol for postoperative analgesia in a 4 day-old term neonate.  PaediatrAnaesth 2007;17(1):70-1. 
  25. Wilson-Smith EM, Morton NS. Survey of I.V. paracetamol  (acetaminophen) use in neonates and infants under 1 year of age by  UK anesthetists. PaediatrAnaesth 2009;19(4):329-37. 
  26. Jacqz-Aigrain E, Anderson BJ. Pain control: nonsteroidal anti inflammatory agents. Semin Fetal Neonat Med 2006;11(4):329-37.
  27. Struthmann L, Hellwig N, Pircger J, et al. Prothrombotic effects of  diclofenac on arteriolar platelet activation and thrombosis in vivo. J  ThrombHaemost 2009;7(10):1727-35. 
  28. Sheffield MJ, Schmutz N, Lambert DK, Henry E, Christensen RD.  Ibuprofen lysine administration to neonates with a patent ductus  arteriosus: effect on platelet plug formation assessed by in vivo and  in vitro measurements. J Perinatol2009;29(1):39-43. 
  29. Boo NY, Mohd Amin I, Bilkis A, Yoniosus-Junina F. Predictors  of failed closure of patent ductus arteriosus with indomethacin.  Singapore Med J 2006;47(9):763-8. 
  30. Ahlfors CE. Effects of ibuprofen on bilirubin-albumin binding. J  Pediatr 2004;3:386-8. 
  31. Heyman E, Morag I. Batash D. Keidar R. Baram S. Berkovitch M.  Closure of patent ductus arteriosus with oral ibuprofen suspension  in premature infants: a pilot study. Pediatrics 2003;112(5):e354. 
  32. Terrin G, Conte F, Scipione, A, et al. Efficacy of paracetamol for  the treatment of patent ductus arteriosus in preterm neonates. Ital J  Pediatr 2014;40:21.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.